Similar companies
Income Statement (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Revenue | 7.6M | 23.7% |
| Gross Profit | 7.6M | 23.7% |
| Operating expense | 77M | 10.9% |
| Net Income | -59M | 31% |
| EBITDA | -40M | 2.3% |
Balance Sheet (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 383M | 5% |
| Total Liabilities | 871M | 21.4% |
| Shares Outstanding | 735M | 5.2% |
Cash Flow (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | -85M | 13.8% |
| Cash from financing | 107M | 586.2% |
EPS
Financial Highlights for Immunitybio in Q4 '24
Immunitybio reported a revenue of 7.6M, which is a 23.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 7.6M, marking a 23.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 77M, showing a -10.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -59M, showing a 31% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -40M, showing a 2.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Immunitybio with growth in revenue, gross profit, and net income.
